US 9248132
Compositions and methods for inhibition of the JAK pathway
granted A61KA61K31/155A61K31/506
Quick answer
US patent 9248132 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Feb 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 1
- CPC classes
- A61K, A61K31/155, A61K31/506, A61K31/5377, A61K31/538